OA10600A - Salts of an anti-migraine indole derivative - Google Patents

Salts of an anti-migraine indole derivative Download PDF

Info

Publication number: OA10600A
Authority: OA; OAPI
Prior art keywords: compound; formula; daims; suitable solvent; polymorphic form
Prior art date: 1994-08-27

Application number

OA60969A

Other languages

English (en)

Inventor

Valerie Denise Harding

Ross James Macrae

Ronald James Ogilvie

Original Assignee

Pfizer Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-27

Filing date

1997-02-27

Publication date

2000-04-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10760474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10600(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-02-27 Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev

2000-04-06 Publication of OA10600A publication Critical patent/OA10600A/en

Links

150000003839 salts Chemical class 0.000 title description 9
230000002460 anti-migrenic effect Effects 0.000 title description 2
150000002475 indoles Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 30
238000000034 method Methods 0.000 claims abstract description 14
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 40
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
239000002904 solvent Substances 0.000 claims description 17
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 15
239000000203 mixture Substances 0.000 claims description 14
239000000243 solution Substances 0.000 claims description 14
238000011282 treatment Methods 0.000 claims description 13
229910000042 hydrogen bromide Inorganic materials 0.000 claims description 11
239000007864 aqueous solution Substances 0.000 claims description 9
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 8
238000000634 powder X-ray diffraction Methods 0.000 claims description 8
238000010521 absorption reaction Methods 0.000 claims description 7
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
239000010439 graphite Substances 0.000 claims description 6
229910002804 graphite Inorganic materials 0.000 claims description 6
238000002329 infrared spectrum Methods 0.000 claims description 6
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
239000000556 agonist Substances 0.000 claims description 5
229910052802 copper Inorganic materials 0.000 claims description 5
239000010949 copper Substances 0.000 claims description 5
239000007909 solid dosage form Substances 0.000 claims description 5
206010059245 Angiopathy Diseases 0.000 claims description 4
208000019901 Anxiety disease Diseases 0.000 claims description 4
206010009094 Chronic paroxysmal hemicrania Diseases 0.000 claims description 4
208000006561 Cluster Headache Diseases 0.000 claims description 4
206010013654 Drug abuse Diseases 0.000 claims description 4
208000030814 Eating disease Diseases 0.000 claims description 4
208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
206010020772 Hypertension Diseases 0.000 claims description 4
208000008589 Obesity Diseases 0.000 claims description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
206010047700 Vomiting Diseases 0.000 claims description 4
230000036506 anxiety Effects 0.000 claims description 4
208000018912 cluster headache syndrome Diseases 0.000 claims description 4
238000002425 crystallisation Methods 0.000 claims description 4
235000014632 disordered eating Nutrition 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
235000020824 obesity Nutrition 0.000 claims description 4
208000007777 paroxysmal Hemicrania Diseases 0.000 claims description 4
238000010992 reflux Methods 0.000 claims description 4
208000011117 substance-related disease Diseases 0.000 claims description 4
208000019553 vascular disease Diseases 0.000 claims description 4
206010019233 Headaches Diseases 0.000 claims description 3
238000009109 curative therapy Methods 0.000 claims description 3
231100000869 headache Toxicity 0.000 claims description 3
238000011321 prophylaxis Methods 0.000 claims description 3
230000005855 radiation Effects 0.000 claims description 3
239000011541 reaction mixture Substances 0.000 claims description 3
239000010779 crude oil Substances 0.000 claims description 2
238000010438 heat treatment Methods 0.000 claims description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 2
230000001225 therapeutic effect Effects 0.000 abstract 1
239000003826 tablet Substances 0.000 description 14
-1 3,5-disubstituted indoles Chemical class 0.000 description 11
239000007787 solid Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
OJYGBLRPYBAHRT-UHFFFAOYSA-N alphachloralose Chemical compound O1C(C(Cl)(Cl)Cl)OC2C(O)C(C(O)CO)OC21 OJYGBLRPYBAHRT-UHFFFAOYSA-N 0.000 description 8
238000002844 melting Methods 0.000 description 8
239000002775 capsule Substances 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
238000007906 compression Methods 0.000 description 7
230000006835 compression Effects 0.000 description 7
PWVXXGRKLHYWKM-LJQANCHMSA-N eletriptan Chemical class CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 PWVXXGRKLHYWKM-LJQANCHMSA-N 0.000 description 7
230000008018 melting Effects 0.000 description 7
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
239000008101 lactose Substances 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
208000019695 Migraine disease Diseases 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
238000001816 cooling Methods 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
UTINOWOSWSPFLJ-FSRHSHDFSA-N eletriptan hydrobromide Chemical compound Br.CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 UTINOWOSWSPFLJ-FSRHSHDFSA-N 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000008187 granular material Substances 0.000 description 4
206010027599 migraine Diseases 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
229920002785 Croscarmellose sodium Polymers 0.000 description 3
235000019759 Maize starch Nutrition 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
238000005056 compaction Methods 0.000 description 3
229960001681 croscarmellose sodium Drugs 0.000 description 3
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
238000011161 development Methods 0.000 description 3
238000000113 differential scanning calorimetry Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000008298 dragée Substances 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000001144 powder X-ray diffraction data Methods 0.000 description 3
239000002002 slurry Substances 0.000 description 3
238000004448 titration Methods 0.000 description 3
230000007704 transition Effects 0.000 description 3
SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
101000973200 Homo sapiens Nuclear factor 1 C-type Proteins 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
229910002651 NO3 Inorganic materials 0.000 description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
102100022162 Nuclear factor 1 C-type Human genes 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
101000973172 Sus scrofa Nuclear factor 1 Proteins 0.000 description 2
239000002253 acid Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
239000003921 oil Substances 0.000 description 2
239000006190 sub-lingual tablet Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
QZAYGJVTTNCVMB-PZFLKRBQSA-N 3-(2-amino-1,2-ditritioethyl)-1h-indol-5-ol Chemical compound C1=C(O)C=C2C(C([3H])C(N)[3H])=CNC2=C1 QZAYGJVTTNCVMB-PZFLKRBQSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
RLJFTICUTYVZDG-UHFFFAOYSA-N Methiothepine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2CC1N1CCN(C)CC1 RLJFTICUTYVZDG-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000003420 antiserotonin agent Substances 0.000 description 1
230000008321 arterial blood flow Effects 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000001938 differential scanning calorimetry curve Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
238000000227 grinding Methods 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940116871 l-lactate Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000008213 purified water Substances 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
210000003752 saphenous vein Anatomy 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000646 scanning calorimetry Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
229960003708 sumatriptan Drugs 0.000 description 1
239000000829 suppository Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Addiction (AREA)
Heart & Thoracic Surgery (AREA)
Otolaryngology (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Toxicology (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Reciprocating, Oscillating Or Vibrating Motors (AREA)

OA60969A 1994-08-27 1997-02-27 Salts of an anti-migraine indole derivative OA10600A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB9417310A GB9417310D0 (en)	1994-08-27	1994-08-27	Therapeutic agents

Publications (1)

Publication Number	Publication Date
OA10600A true OA10600A (en)	2000-04-06

Family

ID=10760474

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA60969A OA10600A (en)	1994-08-27	1997-02-27	Salts of an anti-migraine indole derivative

Country Status (45)

Country	Link
US (2)	US6110940A (fr)
EP (1)	EP0776323B1 (fr)
JP (1)	JP2904588B2 (fr)
KR (1)	KR100228952B1 (fr)
CN (1)	CN1066727C (fr)
AP (1)	AP576A (fr)
AT (1)	ATE163182T1 (fr)
AU (1)	AU691005B2 (fr)
BG (1)	BG61840B1 (fr)
BR (1)	BRPI9503812B1 (fr)
CA (1)	CA2198599C (fr)
CO (1)	CO4410334A1 (fr)
CZ (1)	CZ287693B6 (fr)
DE (1)	DE69501620T2 (fr)
DK (1)	DK0776323T3 (fr)
DZ (1)	DZ1923A1 (fr)
EG (1)	EG23822A (fr)
ES (1)	ES2112650T3 (fr)
FI (1)	FI113768B (fr)
GB (1)	GB9417310D0 (fr)
GR (1)	GR3026475T3 (fr)
HR (1)	HRP950460B1 (fr)
HU (1)	HU227822B1 (fr)
IL (1)	IL115013A (fr)
IS (1)	IS1850B (fr)
LV (1)	LV11800B (fr)
MA (1)	MA23650A1 (fr)
MX (1)	MX9701538A (fr)
MY (1)	MY113733A (fr)
NO (1)	NO311297B1 (fr)
NZ (1)	NZ288210A (fr)
OA (1)	OA10600A (fr)
PE (1)	PE41596A1 (fr)
PL (1)	PL180867B1 (fr)
RO (1)	RO116400B1 (fr)
RU (1)	RU2159241C2 (fr)
SA (1)	SA95160156B1 (fr)
SI (1)	SI9520091B (fr)
SK (1)	SK282922B6 (fr)
TN (1)	TNSN95092A1 (fr)
TR (1)	TR199501061A2 (fr)
UA (1)	UA45980C2 (fr)
WO (1)	WO1996006842A1 (fr)
YU (1)	YU49287B (fr)
ZA (1)	ZA957142B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9420529D0 (en)	1994-10-12	1994-11-30	Pfizer Ltd	Indoles
GB9706089D0 (en) *	1997-03-24	1997-05-14	Scherer Ltd R P	Pharmaceutical composition
EP0999841B1 (fr) *	1997-07-03	2001-10-17	Pfizer Limited	Compositions pharmaceutiques contenant l'hemisulfate d'eletriptane et de la cafeine
GB9714081D0 (en) *	1997-07-03	1997-09-10	Pfizer Ltd	Pharmaceutical compositions
GB9816556D0 (en) *	1998-07-30	1998-09-30	Pfizer Ltd	Therapy
GB9825988D0 (en) *	1998-11-27	1999-01-20	Pfizer Ltd	Indole derivatives
GB9922963D0 (en) *	1999-09-28	1999-12-01	Pfizer Ltd	Polymorphic salt
GB9915231D0 (en)	1999-06-29	1999-09-01	Pfizer Ltd	Pharmaceutical complex
GB9923314D0 (en)	1999-10-01	1999-12-08	Pfizer Ltd	Acylation process
CA2324116A1 (fr) *	1999-10-25	2001-04-25	Susan Beth Sobolov-Jaynes	Antagonistes du recepteur nk-1 et eletriptan pour le traitement de la migraine
US6977723B2 (en)	2000-01-07	2005-12-20	Transform Pharmaceuticals, Inc.	Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
US7108970B2 (en)	2000-01-07	2006-09-19	Transform Pharmaceuticals, Inc.	Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
GB0008563D0 (en)	2000-04-07	2000-05-24	Cambridge Discovery Chemistry	Investigating different physical and/or chemical forms of materials
GB0018968D0 (en) *	2000-08-02	2000-09-20	Pfizer Ltd	Particulate composition
US20030166704A1 (en) *	2000-12-20	2003-09-04	Pfizer Inc.	New process
GB0031094D0 (en) *	2000-12-20	2001-01-31	Pfizer Ltd	New Process
US6579898B2 (en)	2001-03-01	2003-06-17	Pfizer Inc.	Compositions having improved bioavailability
WO2004089365A1 (fr)	2003-04-11	2004-10-21	Pfizer Limited	Combinaison pharmaceutique a base d'eletriptan et de bicarbonate de sodium
GB0312478D0 (en) *	2003-05-30	2003-07-09	Pfizer Ltd	Improved process
US7132549B2 (en)	2003-05-30	2006-11-07	Pfizer Inc.	Process
US6927296B2 (en)	2003-07-23	2005-08-09	Pfizer Inc.	Process
GB0317229D0 (en) *	2003-07-23	2003-08-27	Pfizer Ltd	Improved process
US7241805B2 (en) *	2005-06-27	2007-07-10	Biovail Laboratories, Inc.	Modified release formulations of a bupropion salt
RU2313340C1 (ru) *	2006-02-20	2007-12-27	Дмитрий Владимирович Зимин	Лекарственное средство, обладающее противомигренозным действием, и способ его изготовления
WO2008049116A2 (fr) *	2006-10-19	2008-04-24	Auspex Pharmaceuticals, Inc.	Indoles substitués
US20080139510A1 (en) *	2006-12-07	2008-06-12	Abe Rose	Treatment of migraine headaches with sublingual amino acids
EP1956018A1 (fr) *	2007-02-06	2008-08-13	Boehringer Ingelheim Pharma GmbH & Co. KG	Procédé de préparation d'un dérivé du benzimidazole
EP2046777A2 (fr)	2007-05-01	2009-04-15	Plus Chemicals B.V.	Bromhydrate d'élétriptan amorphe et son procédé de préparation, et autres formes de bromhydrate d'élétriptan
US20080319205A1 (en) *	2007-05-29	2008-12-25	Roman Bednar	Process for preparing 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole
EP2225224A2 (fr) *	2007-12-17	2010-09-08	Actavis Group PTC EHF	Sel semioxalate innovant de l'élétriptan
WO2009142771A2 (fr) *	2008-05-22	2009-11-26	Plus Chemicals, S.A.	Sels de (r)-5-(2-phénylsulfonyléthényl)-3-(n-méthylpyrrolidin-2-ylméthyl)-1h-indole, de 5-bromo-3-[(r)-1-méthyl-pyrrolidin-2-ylméthyl]-1h-indole et d’élétryptan
US8349900B2 (en) *	2008-08-07	2013-01-08	Valeant International Bermuda	Bupropion hydrobromide polymorphs
WO2010097703A1 (fr) *	2009-02-25	2010-09-02	Actavis Group Ptc Ehf	Elétriptan de pureté élevée ou un de ses sels pharmaceutiquement acceptables essentiellement exempt d'impuretés n-oxydes d'élétriptan
WO2010116386A2 (fr) *	2009-04-08	2010-10-14	Biophore India Pharmaceuticals Pvt. Ltd.	Nouveau polymorphe de bromhydrate d'életriptan et son procédé de fabrication
IT1393700B1 (it)	2009-04-22	2012-05-08	F S I Fabbrica Italiana Sint	Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (fr)	2009-06-25	2011-01-13	Matrix Laboratories Ltd	Procédé amélioré d'élaboration d'élétriptane et son sel correspondant
WO2011089614A1 (fr) *	2010-01-19	2011-07-28	Sms Pharmaceuticals Limited	Procédé de préparation de bromhydrate d'élétriptan ayant une forme α
WO2014063752A1 (fr)	2012-10-26	2014-05-01	Synthon Bv	Procédé de production de la forme cristalline alpha du bromhydrure d'élétriptan
WO2017125351A1 (fr)	2016-01-21	2017-07-27	Laboratorios Lesvi Sl	Procédé de préparation de ((r)-3-[(-1-méthylpyrrolidin-2-yl)méthyl]-5-(2-phénylsulfonyléthyl)-1h-indole

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2773875A (en) *	1952-03-28	1956-12-11	Hoffmann La Roche	Indole derivatives and method for producing same
GB886684A (en) *	1957-09-17	1962-01-10	Upjohn Co	Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) *	1958-02-25	1960-10-19	Rhone Poulenc Sa	New indole derivatives
US3037031A (en) *	1959-08-04	1962-05-29	Warner Lambert Pharmaceutical	Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) *	1960-03-01	1962-04-11	Roche Products Ltd	Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) *	1961-04-06	1964-08-12	Parke Davis & Co	Amine compounds and means of producing the same
US4092315A (en) *	1976-03-01	1978-05-30	Pfizer Inc.	Novel crystalline forms of prazosin hydrochloride
ZA795239B (en) *	1978-10-12	1980-11-26	Glaxo Group Ltd	Heterocyclic compounds
ZW19381A1 (en) *	1980-08-12	1983-03-09	Glaxo Group Ltd	Heterocyclic compounds
US4803218A (en) *	1982-09-29	1989-02-07	Mcneilab, Inc.	3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) *	1986-01-08	1986-02-12	Glaxo Group Ltd	Chemical compounds
DK158590D0 (da) *	1990-07-02	1990-07-02	Lundbeck & Co As H	Indolderivater
HU225055B1 (en) *	1990-10-15	2006-05-29	Pfizer	Indole derivatives, their intermediates, process for production them and pharmaceutical compositions containing the compounds
US5578612A (en) *	1990-10-15	1996-11-26	Pfizer Inc.	Indole derivatives
US5559129A (en) *	1990-10-15	1996-09-24	Pfizer Inc	Indole derivatives
US5559246A (en) *	1990-10-15	1996-09-24	Pfizer Inc.	Indole derivatives
US5545644A (en) *	1990-10-15	1996-08-13	Pfizer Inc.	Indole derivatives
US5208248A (en) *	1991-01-11	1993-05-04	Merck Sharpe & Dohme, Ltd.	Indazole-substituted five-membered heteroaromatic compounds
CZ283018B6 (cs) *	1991-02-01	1997-12-17	Merck Sharp And Dohme Limited	Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
CA2124206C (fr) *	1991-11-25	2001-02-27	John Eugene Macor	Derives indole
GB9201038D0 (en) *	1992-01-16	1992-03-11	Glaxo Group Ltd	Chemical compounds
US5409941A (en) *	1992-02-03	1995-04-25	Pfizer Inc.	5-heteroyl indole derivatives
TW288010B (fr) *	1992-03-05	1996-10-11	Pfizer
AU670579B2 (en) *	1992-04-07	1996-07-25	Pfizer Inc.	Indole derivatives as 5-HT1 agonists
EP0635015B1 (fr) *	1992-04-10	1997-01-29	Pfizer Inc.	Derives d'acylaminoindole utilises en tant qu'agonistes de 5-ht1
GB9207930D0 (en) *	1992-04-10	1992-05-27	Pfizer Ltd	Indoles
GB9208161D0 (en) *	1992-04-14	1992-05-27	Pfizer Ltd	Indoles
GB9210400D0 (en) *	1992-05-15	1992-07-01	Merck Sharp & Dohme	Therapeutic agents
FR2701026B1 (fr) *	1993-02-02	1995-03-31	Adir	Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
KR960701865A (ko) *	1993-04-22	1996-03-28	데이비드 존. 우드	편두통에 사용하는 5-HT1 유사 효능제인 인돌 유도체(Indole Derivatives as 5-HT, -Like Agonists for Use in Migraine)
AP486A (en) *	1993-04-27	1996-04-16	Pfizer	Indole derivatives.
AU686654B2 (en) *	1993-08-31	1998-02-12	Pfizer Inc.	5-arylindole derivatives

1994
- 1994-08-27 GB GB9417310A patent/GB9417310D0/en active Pending
1995
- 1995-05-17 CN CN95194697A patent/CN1066727C/zh not_active Expired - Lifetime
- 1995-05-17 WO PCT/EP1995/001914 patent/WO1996006842A1/fr not_active Ceased
- 1995-05-17 KR KR1019970701281A patent/KR100228952B1/ko not_active Expired - Lifetime
- 1995-05-17 RO RO97-00375A patent/RO116400B1/ro unknown
- 1995-05-17 UA UA97031432A patent/UA45980C2/uk unknown
- 1995-05-17 NZ NZ288210A patent/NZ288210A/en not_active IP Right Cessation
- 1995-05-17 DE DE69501620T patent/DE69501620T2/de not_active Expired - Lifetime
- 1995-05-17 MX MX9701538A patent/MX9701538A/es active IP Right Grant
- 1995-05-17 HU HU9701704A patent/HU227822B1/hu unknown
- 1995-05-17 DK DK95922465.0T patent/DK0776323T3/da active
- 1995-05-17 SK SK248-97A patent/SK282922B6/sk not_active IP Right Cessation
- 1995-05-17 CA CA002198599A patent/CA2198599C/fr not_active Expired - Lifetime
- 1995-05-17 AU AU27352/95A patent/AU691005B2/en not_active Expired
- 1995-05-17 JP JP8508431A patent/JP2904588B2/ja not_active Expired - Lifetime
- 1995-05-17 PL PL95318319A patent/PL180867B1/pl unknown
- 1995-05-17 SI SI9520091A patent/SI9520091B/sl unknown
- 1995-05-17 RU RU97104885/04A patent/RU2159241C2/ru active
- 1995-05-17 US US08/776,680 patent/US6110940A/en not_active Expired - Lifetime
- 1995-05-17 EP EP95922465A patent/EP0776323B1/fr not_active Expired - Lifetime
- 1995-05-17 ES ES95922465T patent/ES2112650T3/es not_active Expired - Lifetime
- 1995-05-17 CZ CZ1997563A patent/CZ287693B6/cs not_active IP Right Cessation
- 1995-05-17 AT AT95922465T patent/ATE163182T1/de active
- 1995-07-27 AP APAP/P/1995/000754A patent/AP576A/en active
- 1995-08-14 SA SA95160156A patent/SA95160156B1/ar unknown
- 1995-08-16 TN TNTNSN95092A patent/TNSN95092A1/fr unknown
- 1995-08-21 MA MA23992A patent/MA23650A1/fr unknown
- 1995-08-21 IL IL11501395A patent/IL115013A/xx not_active IP Right Cessation
- 1995-08-23 CO CO95037815A patent/CO4410334A1/es unknown
- 1995-08-23 DZ DZ950104A patent/DZ1923A1/fr active
- 1995-08-23 PE PE1995277098A patent/PE41596A1/es not_active IP Right Cessation
- 1995-08-25 BR BRPI9503812A patent/BRPI9503812B1/pt not_active IP Right Cessation
- 1995-08-25 MY MYPI95002536A patent/MY113733A/en unknown
- 1995-08-25 ZA ZA9507142A patent/ZA957142B/xx unknown
- 1995-08-25 YU YU56995A patent/YU49287B/sh unknown
- 1995-08-25 HR HR9417310.1A patent/HRP950460B1/xx not_active IP Right Cessation
- 1995-08-25 TR TR95/01061A patent/TR199501061A2/xx unknown
- 1995-08-26 EG EG71195A patent/EG23822A/xx active
1996
- 1996-12-19 IS IS4401A patent/IS1850B/is unknown
1997
- 1997-02-20 BG BG101250A patent/BG61840B1/bg unknown
- 1997-02-26 LV LVP-97-34A patent/LV11800B/en unknown
- 1997-02-26 FI FI970800A patent/FI113768B/fi not_active IP Right Cessation
- 1997-02-26 NO NO19970861A patent/NO311297B1/no not_active IP Right Cessation
- 1997-02-27 OA OA60969A patent/OA10600A/en unknown
1998
- 1998-03-27 GR GR980400660T patent/GR3026475T3/el unknown
2000
- 2000-06-15 US US09/596,017 patent/US6380226B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
MY113733A (en)	2002-05-31
JPH09512283A (ja)	1997-12-09
BR9503812A (pt)	1996-04-16
IS4401A (is)	1996-12-19
CN1155886A (zh)	1997-07-30
NO311297B1 (no)	2001-11-12
PL318319A1 (en)	1997-06-09
US6110940A (en)	2000-08-29
LV11800A (lv)	1997-06-20
HRP950460B1 (en)	2000-02-29
DK0776323T3 (da)	1998-03-30
FI113768B (fi)	2004-06-15
BG61840B1 (bg)	1998-07-31
HRP950460A2 (en)	1997-08-31
FI970800L (fi)	1997-02-26
SA95160156B1 (ar)	2005-05-30
MA23650A1 (fr)	1996-04-01
PE41596A1 (es)	1996-10-12
IL115013A0 (en)	1995-12-08
MX9701538A (es)	1997-05-31
BG101250A (en)	1997-09-30
CA2198599C (fr)	2000-06-06
NO970861D0 (no)	1997-02-26
DE69501620T2 (de)	1998-07-02
YU49287B (sh)	2005-03-15
CA2198599A1 (fr)	1996-03-07
GR3026475T3 (en)	1998-06-30
SI9520091B (sl)	2004-10-31
GB9417310D0 (en)	1994-10-19
KR970705557A (ko)	1997-10-09
YU56995A (sh)	1998-07-10
TR199501061A2 (tr)	1996-06-21
LV11800B (en)	1997-10-20
IS1850B (is)	2003-02-07
AU2735295A (en)	1996-03-22
WO1996006842A1 (fr)	1996-03-07
SK282922B6 (sk)	2003-01-09
CZ287693B6 (en)	2001-01-17
NZ288210A (en)	1998-01-26
RO116400B1 (ro)	2001-01-30
KR100228952B1 (ko)	1999-11-01
BRPI9503812B1 (pt)	2017-04-18
FI970800A0 (fi)	1997-02-26
SI9520091A (sl)	1998-02-28
EP0776323A1 (fr)	1997-06-04
CO4410334A1 (es)	1997-01-09
ES2112650T3 (es)	1998-04-01
HU227822B1 (en)	2012-03-28
US6380226B1 (en)	2002-04-30
NO970861L (no)	1997-02-26
IL115013A (en)	2000-11-21
SK24897A3 (en)	1998-08-05
TNSN95092A1 (fr)	1996-02-06
AP576A (en)	1997-03-20
AU691005B2 (en)	1998-05-07
JP2904588B2 (ja)	1999-06-14
EG23822A (en)	2007-09-19
RU2159241C2 (ru)	2000-11-20
DZ1923A1 (fr)	2002-02-17
EP0776323B1 (fr)	1998-02-11
HUT77310A (hu)	1998-03-30
DE69501620D1 (de)	1998-03-19
ATE163182T1 (de)	1998-02-15
PL180867B1 (pl)	2001-04-30
CZ56397A3 (cs)	1998-05-13
AP9500754A0 (en)	1995-07-31
CN1066727C (zh)	2001-06-06
ZA957142B (en)	1997-02-25
UA45980C2 (uk)	2002-05-15

Publication	Publication Date	Title
US6110940A (en)	2000-08-29	Salts of an anti-migraine indole derivative
CN111100078A (zh)	2020-05-05	3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲及其盐的晶型
JP2000506847A (ja)	2000-06-06	４―アミノ―ピリミジン誘導体、これらの化合物を含む医薬品、それらの使用及び製造法
JP2008534470A (ja)	2008-08-28	Ｄｐｐ−ｉｖ阻害剤の新規な塩及び多形
JP7338950B2 (ja)	2023-09-05	（ｓ）－［３，４－ジフルオロ－２－（２－フルオロ－４－ヨードフェニルアミノ）フェニル］［３－ヒドロキシ－３－（ピペリジン－２－イル」）アゼチジン－１－イル］－メタノンの結晶性フマル酸塩
US20010049439A1 (en)	2001-12-06	Therapeutic polymorphs of a GABA-A alpha-5 inverse agonist and pamoate formulations of the same
JP2015514741A (ja)	2015-05-21	結晶形態の（Ｓ）−４−アミノ−Ｎ−（１−（４−クロロフェニル）−３−ヒドロキシプロピル）−１−（７Ｈ−ピロロ［２，３−ｄ］−ピリミジン−４−イル）ピペリジン−４−カルボキサミド
CA2379572C (fr)	2006-11-14	Sel polymorphe
HRP20010181A2 (en)	2002-04-30	N-substituted azabicycloheptane derivatives, production and use thereof